Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience announced new preclinical results for its bispecific antibody, ATOR-4066, at the 9th International Cancer Immunotherapy Conference. The findings indicate that ATOR-4066 effectively stimulates myeloid and T cells within tumors, leading to significant anti-tumor effects and limited immune activation outside the tumor. These results support further development of ATOR-4066 as a promising candidate for transforming treatment outcomes in solid tumors.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, an immuno-oncology approach that enhances T cell priming and counters the immunosuppressive nature of the tumor microenvironment. Alligator’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development, having shown promising results in metastatic pancreatic cancer patients.
Average Trading Volume: 506,974
Technical Sentiment Signal: Sell
Current Market Cap: SEK140.6M
For a thorough assessment of ATORX stock, go to TipRanks’ Stock Analysis page.